The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients

NCT05008926 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

370

Enrollment

OTHER

Sponsor class

Conditions

Brain Injuries

Interventions

DRUG: Naloxegol
DRUG: Placebo

Sponsor

University Hospital, Brest